G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
88 hedge funds and large institutions have $45.5M invested in G1 Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 33 increasing their positions, 17 reducing their positions, and 24 closing their positions.
94% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 17
43% more call options, than puts
Call options by funds: $8.85M | Put options by funds: $6.18M
2% more funds holding
Funds holding: 86 → 88 (+2)
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
26% less capital invested
Capital invested by funds: $61.6M → $45.5M (-$16.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.21M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$5.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.55M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.19M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.63M |
| 2 |
Millennium Management
New York
|
-$1.93M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.15M |
| 4 |
Jane Street
New York
|
-$1.03M |
| 5 |
Goldman Sachs
New York
|
-$907K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
YIH
101
Y-Intercept (HK)
Hong Kong
| – | -$115K | -26,703 | Closed |
|
|
SSA
102
Schonfeld Strategic Advisors
New York
| – | -$86.6K | -20,042 | Closed |
|
|
JFG
103
Jefferies Financial Group
New York
| – | -$69.6K | -16,100 | Closed |
|
104
Balyasny Asset Management
Chicago,
Illinois
| – | -$67.5K | -15,614 | Closed |
|
|
PAS
105
Point72 Asia (Singapore)
Singapore
| – | -$64.8K | -14,991 | Closed |
|
|
OAM
106
Oxford Asset Management
Oxford,
United Kingdom
| – | -$63.5K | -14,703 | Closed |
|
|
FAIM
107
Financial Advocates Investment Management
Olympia,
Washington
| – | -$62.4K | -14,450 | Closed |
|
|
LP
108
LMR Partners
London,
United Kingdom
| – | -$61.4K | -14,216 | Closed |
|
|
CAS
109
CTC Alternative Strategies
Chicago,
Illinois
| – | -$51.8K | -12,000 | Closed |
|
|
QT
110
Quantbot Technologies
New York
| – | -$38K | -8,800 | Closed |
|
111
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$6 | -1,338 | Closed |
|
112
Lazard Asset Management
New York
| – | -$1K | -298 | Closed |
|
GTHX Hedge Fund Activity: Q2 2024 in Review
88 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q2 2024, worth a combined $45.5M — down 26% from $61.6M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new GTHX positions and 24 closed out — a net gain of 2 holders — while 33 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock, adding an estimated $9.21M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $3.63M sold.
- 88 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q2 2024, up from 86 in Q1 2024.
- Funds reported $45.5M of G1 Therapeutics, Inc. Common Stock stock for Q2 2024, down 26% quarter-over-quarter.
- 26 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q2 2024 and 24 closed out, a net change of +2 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q2 2024 was BlackRock, an estimated $9.21M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q2 2024 was Susquehanna International Group, an estimated $3.63M sold.
Based on aggregated 13F filings for Q2 2024.